life science

life science

FDA Requires Additional Trials For Catalyst Pharmaceuticals’ Rare Disease Drug

11h ago
SOURCE  

Description

On www.xtalks.com - Just two months after Catalyst Pharmaceuticals received a rarely-issued Refuse to File letter from the US Food and Drug Administration (FDA), the biotech has faced more hurdles with the regulatory agency. To read more: http://www.xtalks.com/Catalyst-Pharmaceuticals-Rare-Disease-Drug-323.ashx For more news stories, visit: http://xtalks.com/News.ashx Receive weekly news updates right in your inbox: http://www.xtalks.com/subscribe.ashx Listen live and interact with featured speakers on our upcoming Life Science webinars: http://xtalks.com/upcoming.ashx